Metabolism and mental illness

Trends in Molecular Medicine

Volumn 22, Issue 2, 2016, Pages 174-183

  Sestan Pesa, Matija ^a   Horvath, Tamas L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCANNABINOID; GASTROINTESTINAL HORMONE; GHRELIN; INSULIN; LEPTIN; SEROTONIN; ANTIDEPRESSANT AGENT; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 4;

BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; DEPRESSION; EATING DISORDER; FEEDING; FEEDING BEHAVIOR; HUMAN; HYPOTHALAMUS; MENTAL DISEASE; METABOLIC DISORDER; MOOD DISORDER; NONHUMAN; OBESITY; REVIEW; SEROTONINERGIC SYSTEM; BRAIN CORTEX; DRUG EFFECTS; FEEDING AND EATING DISORDERS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANTIDEPRESSIVE AGENTS; CEREBRAL CORTEX; DEPRESSION; FEEDING AND EATING DISORDERS; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GHRELIN; HUMANS; HYPOTHALAMUS; INSULIN; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEPTIN; OBESITY; SEROTONIN; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 84960373844     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.12.003     Document Type: Review

References (89)

1. Pratt L.A., Brody D.J. Depression in the U.S. household population, 2009-2012. NCHS Data Brief 2014, 172:1-8.
2. Ng M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:766-781.
3. Kishi T., Elmquist J.K. Body weight is regulated by the brain: a link between feeding and emotion. Mol. Psychiatry 2005, 10:132-146.
4. Pratt L.A., Brody D.J. Depression and obesity in the U.S. adult household population, 2005-2010. NCHS Data Brief 2014, 167:1-8.
5. Aronne L.J., Segal K.R. Weight gain in the treatment of mood disorders. J. Clin. Psychiatry 2003, 64(Suppl. 8):22-29.
6. Godart N., et al. Mood disorders in eating disorder patients: prevalence and chronology of ONSET. J. Affect. Disord. 2015, 185:115-122.
7. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol. Behav. 2007, 92:263-271.
8. Sohn J.W., et al. Neuronal circuits that regulate feeding behavior and metabolism. Trends Neurosci. 2013, 36:504-512.
9. Xu Y., et al. Central nervous control of energy and glucose balance: focus on the central melanocortin system. Ann. N. Y. Acad. Sci. 2011, 1243:1-14.
10. Smith M.A., et al. Melanocortins and agouti-related protein modulate the excitability of two arcuate nucleus neuron populations by alteration of resting potassium conductances. J. Physiol. 2007, 578:425-438.
11. Yulyaningsih E., et al. NPY receptors as potential targets for anti-obesity drug development. Br. J. Pharmacol. 2011, 163:1170-1202.
12. Roseberry A.G., et al. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 2004, 41:711-722.
13. Chee M.J., et al. Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus. J. Neurosci. 2010, 30:3380-3390.
14. Imbernon M., et al. Hypothalamic KLF4 mediates leptin's effects on food intake via AgRP. Mol. Metab. 2014, 3:441-451.
15. Chaudhri O.B., et al. Can gut hormones control appetite and prevent obesity?. Diabetes Care 2008, 31(Suppl. 2):S284-S289.
16. Enriori P.J., et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab. 2007, 5:181-194.
17. Haleem D.J., et al. Behavioral, hormonal and central serotonin modulating effects of injected leptin. Peptides 2015, 74:1-8.
18. Garcia-San Frutos M., et al. Impaired central insulin response in aged Wistar rats: role of adiposity. Endocrinology 2007, 148:5238-5247.
19. Lv W.S., et al. The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats. Brain Res. 2012, 1444:11-19.
20. Malin S.K., Kashyap S.R. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 2014, 21:323-329.
21. Perry B., Wang Y. Appetite regulation and weight control: the role of gut hormones. Nutr. Diabetes 2012, 2:e26.
22. Kojima M., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
23. Tschop M., et al. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
24. Foster-Schubert K.E., Cummings D.E. Emerging therapeutic strategies for obesity. Endocr. Rev. 2006, 27:779-793.
25. Perez-Tilve D., et al. Ghrelin-induced adiposity is independent of orexigenic effects. FASEB J. 2011, 25:2814-2822.
26. Spencer S.J., et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Biol. Psychiatry 2012, 72:457-465.
27. Poretti M.B., et al. Ghrelin effects expression of several genes associated with depression-like behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 56:227-234.
28. Feijo Fde M., et al. [Serotonin and hypothalamic control of hunger: a review]. Rev. Assoc. Med. Bras. 2011, 57:74-77.
29. Wurtman R.J., et al. Precursor control of neurotransmitter synthesis. Pharmacol. Rev. 1980, 32:315-335.
30. Schwartz D.H., et al. Feeding increases extracellular serotonin in the lateral hypothalamus of the rat as measured by microdialysis. Brain Res. 1989, 479:349-354.
31. Rouch C., et al. Determination, using microdialysis, of hypothalamic serotonin variations in response to different macronutrients. Physiol. Behav. 1999, 65:653-657.
32. Latham C.J., Blundell J.E. Evidence for the effect of tryptophan on the pattern of food consumption in free feeding and food deprived rats. Life Sci. 1979, 24:1971-1978.
33. Morris P., et al. Food intake and selection after peripheral tryptophan. Physiol. Behav. 1987, 40:155-163.
34. Line S.J., et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur. Neuropsychopharmacol. 2011, 21:108-116.
35. Lan M.Y., et al. Serotonin transporter gene promoter polymorphism is associated with body mass index and obesity in non-elderly stroke patients. J. Endocrinol. Invest. 2009, 32:119-122.
36. Hernandez-Munoz S., Camarena-Medellin B. [Role of serotonin transporter gene in eating disorders]. Rev. Colomb. Psiquiatr. 2014, 43:218-224.
37. Carvajal A., et al. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find. Exp. Clin. Pharmacol. 2000, 22:285-290.
38. Vickers S.P., et al. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 2001, 41:200-209.
39. Heisler L.K., et al. Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J. Neurosci. 2007, 27:6956-6964.
40. Garfield A.S., Heisler L.K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 2009, 587:49-60.
41. Dwarkasing J.T., et al. Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling. J. Cachexia Sarcopenia Muscle 2015, 6:84-94.
42. Dwarkasing J.T., et al. Hypothalamic inflammation and food intake regulation during chronic illness. Peptides 2015, Published online July 6, 2015. 10.1016/j.peptides.2015.06.011.
43. Lam D.D., et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008, 149:1323-1328.
44. Rowland N.E., et al. Effect of serotonergic anorectics on food intake and induction of Fos in brain of mice with disruption of melanocortin 3 and/or 4 receptors. Pharmacol. Biochem. Behav. 2010, 97:107-111.
45. Weizman R., et al. Reduced 3H-imipramine binding but unaltered 3H-serotonin uptake in platelets of adolescent enuretics. Psychiatry Res. 1986, 19:37-42.
46. Monteleone P., et al. Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. Br. J. Psychiatry 1998, 172:439-442.
47. Kaye W.H., et al. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am. J. Psychiatry 1984, 141:1598-1601.
48. Ward A., et al. Neuroendocrine, appetitive and behavioural responses to d-fenfluramine in women recovered from anorexia nervosa. Br. J. Psychiatry 1998, 172:351-358.
49. Steiger H. Eating disorders and the serotonin connection: state, trait and developmental effects. J. Psychiatry Neurosci. 2004, 29:20-29.
50. Kaye W.H., et al. Altered serotonin activity in anorexia nervosa after long-term weight restoration Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?. Arch. Gen. Psychiatry 1991, 48:556-562.
51. Gauthier C., et al. Symptoms of depression and anxiety in anorexia nervosa: links with plasma tryptophan and serotonin metabolism. Psychoneuroendocrinology 2014, 39:170-178.
52. Westen D., Harnden-Fischer J. Personality profiles in eating disorders: rethinking the distinction between axis I and axis II. Am. J. Psychiatry 2001, 158:547-562.
53. 11C]WAY-100635. Arch. Gen. Psychiatry 2005, 62:1032-1041.
54. Eddy K.T., et al. Appetite regulatory hormones in women with anorexia nervosa: binge-eating/purging versus restricting type. J. Clin. Psychiatry 2015, 76:19-24.
55. Sebaaly J.C., et al. Use of fluoxetine in anorexia nervosa before and after weight restoration. Ann. Pharmacother. 2013, 47:1201-1205.
56. Marzola E., et al. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS ONE 2015, 10:e0125569.
57. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 1994, 40:288-295.
58. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 1995, 9(Suppl. 4):33-40.
59. Berg K.A., et al. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol. Sci. 2005, 26:625-630.
60. Gryglewski G., et al. Meta-analysis of molecular imaging of serotonin transporters in major depression. J. Cereb. Blood Flow Metab. 2014, 34:1096-1103.
61. Tomita T., et al. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder. PLoS ONE 2014, 9:e98099.
62. Fava M. Weight gain and antidepressants. J. Clin. Psychiatry 2000, 61(Suppl. 11):37-41.
63. Sussman N., et al. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J. Clin. Psychiatry 2001, 62:256-260.
64. Stanquini L.A., et al. Prelimbic cortex 5-HT1A and 5-HT2C receptors are involved in the hypophagic effects caused by fluoxetine in fasted rats. Pharmacol. Biochem. Behav. 2015, 136:31-38.
65. Healy D. Serotonin and depression. BMJ 2015, 350:h1771.
66. Murrough J.W. Ketamine as a novel antidepressant: from synapse to behavior. Clin. Pharmacol. Ther. 2012, 91:303-309.
67. Fournier J.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
68. Kirsch I., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5:e45.
69. Hieronymus F., et al. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol. Psychiatry 2015, Published online April 28, 2015. 10.1038/mp.2015.53.
70. Koch M., et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature 2015, 519:45-50.
71. Horder J., et al. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J. Psychopharmacol. 2012, 26:125-132.
72. Dantzer R. Cytokine, sickness behavior, and depression. Neurol. Clin. 2006, 24:441-460.
73. Plata-Salaman C.R. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000, 16:1009-1012.
74. Whitaker K.W., Reyes T.M. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration. Neuropharmacology 2008, 54:509-520.
75. De La Garza R.2nd Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci. Biobehav. Rev. 2005, 29:761-770.
76. Dantzer R., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
77. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N. Y. Acad. Sci. 2001, 933:222-234.
78. Janszky I., et al. Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. Brain Behav. Immun. 2005, 19:555-563.
79. Beglinger C., et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 280:R1149-R1154.
80. Adrian T.E., et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
81. Keire D.A., et al. Primary structures of PYY [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G126-G131.
82. Cahill F., et al. Serum peptide YY in response to short-term overfeeding in young men. Am. J. Clin. Nutr. 2011, 93:741-747.
83. Schubert M.M., et al. Acute exercise and hormones related to appetite regulation: a meta-analysis. Sports Med. 2014, 44:387-403.
84. Sumithran P., et al. Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 2011, 365:1597-1604.
85. Herrmann C., et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995, 56:117-126.
86. Punjabi M., et al. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Endocrinology 2014, 155:1690-1699.
87. Wynne K., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 2006, 30:1729-1736.
88. Wynne K., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005, 54:2390-2395.
89. Bhat V.K., et al. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem. Pharmacol. 2013, 85:1655-1662.